Catalyst Biosciences Completes First Steps in Reverse Merger Plan
27 déc. 2022 07h00 HE
|
Catalyst Biosciences, Inc.
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5...
Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share
01 sept. 2022 16h05 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the...
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
25 août 2022 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared...
Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation
19 août 2022 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s...
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
15 août 2022 16h05 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second...
Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board
10 août 2022 12h46 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) announced that it has received a notice from JDS1, LLC...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card
03 août 2022 08h00 HE
|
Catalyst Biosciences, Inc.
ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan Catalyst Urges Stockholders to VOTE “FOR” All of the Company’s...
Catalyst Biosciences Publishes New Investor Presentation
01 août 2022 08h30 HE
|
Catalyst Biosciences, Inc.
Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to Stockholders in an...
Catalyst Biosciences Announces Support from Largest Single Stockholder
01 août 2022 07h30 HE
|
Catalyst Biosciences, Inc.
JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst’s Nominees at the Company’s 2022 Annual Meeting Michael Torok from JEC Appointed as an Observer to the Transaction Committee of the...
Catalyst Biosciences Sends Letter to Stockholders
19 juil. 2022 08h00 HE
|
Catalyst Biosciences, Inc.
Reiterates the Board’s Commitment to Expeditiously Distributing All of the Company’s Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior...